Press release 04.02.2026
Women’s health solution gains momentum with an investment from Delphinus Venture Capital
Postpartum health issues have long been underprioritized, despite their potentially serious and long-lasting consequences for women’s lives. This is something Physician and PhD in urogynecology Karl Møller Bek has witnessed through decades of clinical practice. Together with a multidisciplinary team, he has developed a concrete solution addressing postpartum pelvic floor complications. The Danish MedTech startup LevitaCare has now secured an investment from Delphinus Venture Capital.
An overlooked public health challenge
Every year, approximately 60,000 women give birth in Denmark. In the period immediately following childbirth, many experience symptoms such as pelvic heaviness and pain caused by overstretched tissue and muscles. Over time, around 50% of women who give birth vaginally experience postpartum complications such as pelvic organ prolapse and urinary incontinence; conditions that can have significant consequences for quality of life, working life, and self-esteem.
Despite this, postpartum pelvic floor issues are often downplayed, and many women experience a lack of language, recognition, and access to adequate treatment.
Karl Møller Bek has worked in urogynecology for more than four decades and has treated women with pelvic floor injuries occurring both shortly after childbirth and many years later.
“I have met countless women who feel that something is broken, only to be told to do pelvic floor exercises or simply wait. If a football player suffers a muscle injury, compression is applied to support healing. The same principle should naturally be applied after childbirth,” he says.
From clinical insight to a solution supporting women after childbirth
Together with the other founders – CEO Matilde Fevre, midwife Eva Dimon, and engineer Mads Østergaard – Karl Møller Bek is developing a physical support device designed to relieve and support the pelvic floor after vaginal childbirth. The solution has been developed in close dialogue with women living with postpartum complications.
“Postpartum complications are not a niche issue. Half of the world’s population gives birth, and many women live with long-term consequences. When you can develop a solution that makes a real difference for women while addressing a globally overlooked and structurally underserved market, the commercial potential is significant,” says Matilde Fevre, CEO and co-founder of LevitaCare.
With Matilde Fevre at the helm, LevitaCare combines clinical expertise, midwifery insight, and advanced product development with the ambition to improve care for women after childbirth, and to move women’s health higher on both the healthcare and investment agendas.
Women’s health: A massively underinvested market
Today, only around 6% of private health investments are allocated to women’s health, despite women representing half of the world’s population, according to a recent report by the World Economic Forum and BCG. This is a trend Delphinus Venture Capital aims to help reverse.
“Women’s health is a structurally underinvested area. Partly because the investment community has historically not reflected the target population, making it harder to recognize and understand problems one does not experience firsthand, and partly because areas such as postpartum health have long been taboo and lacked a shared language. As these barriers begin to fall, significant commercial and societal potential emerges,” says Katrine Haahr Riisberg, Investment Associate at Delphinus Venture Capital.
The investment in LevitaCare will support the company’s continued product development and path to market. The device is expected to be launched in 2026.
About LevitaCare
LevitaCare is a Danish MedTech startup developing a physical support device designed to relieve and support the pelvic floor after vaginal childbirth. The solution is based on many years of clinical experience within urogynecology and has been developed in close dialogue with women living with postpartum complications. LevitaCare’s ambition is to improve recovery after childbirth and contribute to better quality of life for women.
About Delphinus Venture Capital
Delphinus Venture Capital is a Danish venture fund established in 2025, managing DKK 600 million. The fund is backed by Aarhus University Research Foundation, HEARTLAND, Norlys, and Salling Group, and invests in research-driven innovation and deeptech companies with the potential to create global impact.
For further information
Matilde Fevre, CEO & Co-founder, LevitaCare
matilde@levitacare.dk
+45 36 21 65 43
Katrine Haahr Riisberg, Investment Associate, Delphinus Venture Capital
khr@delphinus.vc
+45 28 83 28 78